go figure why Azer cell has taken priority, When Precision...

go figure why Azer cell has taken priority, When Precision Biosciences was still running the Azer-Cel program (before Imugene took it over), Bristol Myers Squibb was the major pharma partner backing the development, but Bristol Myers Squibb started to back its own CAR T Breyanzi which is a autologous CAR T , but tricky response rate as Breyanzi had initial ORR of 73% (ZUMA-1-like trials), but Azer cell ~100% in initial cohorts (small sample), looks like it was stormy relationship or Bristol Myers Squibb wanted to shut down azer cell to remove the competition, looking at Breyanzi which is FDA approved and Azer cell has out performed Breyanzi in many tests, this has high potential outcome at getting FDA approval and a ripe candidate for BMS rivals to pick this up...